98 related articles for article (PubMed ID: 26697734)
1. Formulation and optimization of oxaliplatin immuno-nanoparticles using Box-Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer.
Tummala S; Gowthamarajan K; Satish Kumar MN; Praveen TK; Yamjala K; Tripuraneni NS; Prakash A
Artif Cells Nanomed Biotechnol; 2016 Dec; 44(8):1835-1850. PubMed ID: 26697734
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors.
Tummala S; Gowthamarajan K; Satish Kumar MN; Wadhwani A
Drug Deliv; 2016 Jun; 23(5):1773-87. PubMed ID: 26377238
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer.
Tummala S; Gowthamarajan K; Satish Kumar MN
Artif Cells Nanomed Biotechnol; 2017 Mar; 45(2):261-269. PubMed ID: 26933919
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation.
Rajpoot K; Jain SK
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1236-1247. PubMed ID: 28849671
[TBL] [Abstract][Full Text] [Related]
5. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles.
Tummala S; Kumar MN; Pindiprolu SK
Drug Deliv; 2016 Nov; 23(9):3505-3519. PubMed ID: 27295176
[TBL] [Abstract][Full Text] [Related]
6.
Rajpoot K; Jain SK
J Microencapsul; 2020 Dec; 37(8):609-623. PubMed ID: 32985297
[TBL] [Abstract][Full Text] [Related]
7. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity.
Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A
Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
9. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting.
Singh I; Swami R; Pooja D; Jeengar MK; Khan W; Sistla R
J Drug Target; 2016; 24(3):212-23. PubMed ID: 26219519
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.
Zhang K; Geddie ML; Kohli N; Kornaga T; Kirpotin DB; Jiao Y; Rennard R; Drummond DC; Nielsen UB; Xu L; Lugovskoy AA
MAbs; 2015; 7(1):42-52. PubMed ID: 25484041
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer.
Tsai MH; Pan CH; Peng CL; Shieh MJ
Adv Healthc Mater; 2017 Jul; 6(13):. PubMed ID: 28418176
[TBL] [Abstract][Full Text] [Related]
14. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Swami R; Singh I; Jeengar MK; Naidu VG; Khan W; Sistla R
Int J Pharm; 2015; 486(1-2):287-96. PubMed ID: 25839415
[TBL] [Abstract][Full Text] [Related]
15. Application of Box-Behnken design to prepare gentamicin-loaded calcium carbonate nanoparticles.
Maleki Dizaj S; Lotfipour F; Barzegar-Jalali M; Zarrintan MH; Adibkia K
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1475-81. PubMed ID: 25950955
[TBL] [Abstract][Full Text] [Related]
16. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.
Wang F; Chen L; Jiang S; He J; Zhang X; Peng J; Xu Q; Li R
J Liposome Res; 2014 Sep; 24(3):171-81. PubMed ID: 24611687
[TBL] [Abstract][Full Text] [Related]
17. Preliminary pharmacokinetics of PEGylated oxaliplatin polylactic acid nanoparticles in rabbits and tumor-bearing mice.
Wei H; Xu L; Sun Y; Li G; Cui Z; Yan G; Chen Q; Yin H; Ma C
Artif Cells Nanomed Biotechnol; 2015; 43(4):258-62. PubMed ID: 24564351
[TBL] [Abstract][Full Text] [Related]
18. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology.
Gidwani B; Vyas A
Artif Cells Nanomed Biotechnol; 2016; 44(2):571-80. PubMed ID: 25363752
[TBL] [Abstract][Full Text] [Related]
20. KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.
Smakman N; van den Wollenberg DJ; Elias SG; Sasazuki T; Shirasawa S; Hoeben RC; Borel Rinkes IH; Kranenburg O
Cancer Res; 2006 May; 66(10):5403-8. PubMed ID: 16707468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
